Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Racura Oncology Ltd

Capitalization 422M 301M 259M 234M 224M 409M 27.66B 2.75B 1.1B 13.26B 1.13B 1.11B 47.47B P/E ratio 2026 *
-58x
P/E ratio 2027 * -22.5x
Enterprise value 388M 277M 238M 215M 206M 376M 25.45B 2.53B 1.01B 12.2B 1.04B 1.02B 43.69B EV / Sales 2026 *
139x
EV / Sales 2027 * 370x
Free-Float
70.13%
Yield 2026 *
-
Yield 2027 * -
1 day+1.72%
1 week+3.51%
Current month-4.45%
1 month-1.67%
3 months-9.23%
6 months+48.90%
Current year-13.55%
1 week 2.27
Extreme 2.27
2.55
1 month 2.05
Extreme 2.05
2.63
Current year 2.05
Extreme 2.05
3.18
1 year 0.92
Extreme 0.92
4.9
3 years 0.64
Extreme 0.64
4.9
5 years 0.64
Extreme 0.64
4.9
10 years 0.04
Extreme 0.045
4.9
Manager TitleAgeSince
Chief Executive Officer - 22/11/2023
Chief Operating Officer - 01/06/2024
Chief Tech/Sci/R&D Officer - 23/03/2023
Director TitleAgeSince
Chairman 63 01/09/2024
Director/Board Member - 01/01/2025
Director/Board Member - 01/09/2024
Change 5d. change 1-year change 3-years change Capi.($)
+1.72%+3.51%+123.70%+14.56% 301M
+0.03%-0.50%+22.22%+96.01% 45.56B
+3.35%+0.43%+51.85%+17.36% 40.81B
+0.50%-2.14%+96.87%+700.06% 31.01B
-17.88%-16.74%-20.37%-34.18% 21.05B
-1.42%+2.27%+49.79%-28.09% 19.37B
-1.62%-1.62%+27.68%-29.22% 17.15B
-0.09%+20.57%+62.75%+189.79% 13.54B
+3.88%+8.07%-9.23%+995.97% 12.66B
-1.79%+16.72%+65.93% - 12.33B
Average -1.33%+2.78%+47.12%+213.59% 21.38B
Weighted average by Cap. -1.18%+0.81%+40.81%+199.61%

Financials

2026 *2027 *
Net sales 2.8M 2M 1.72M 1.55M 1.49M 2.71M 184M 18.28M 7.32M 88.06M 7.51M 7.35M 315M 1.1M 786K 675K 610K 584K 1.07M 72.16M 7.18M 2.88M 34.59M 2.95M 2.89M 124M
Net income -6.9M -4.93M -4.23M -3.83M -3.66M -6.69M -453M -45.05M -18.04M -217M -18.49M -18.1M -777M -19.4M -13.86M -11.9M -10.75M -10.3M -18.81M -1.27B -127M -50.72M -610M -52M -50.9M -2.18B
Net Debt -33.6M -24M -20.61M -18.63M -17.83M -32.57M -2.2B -219M -87.85M -1.06B -90.06M -88.15M -3.78B -14.4M -10.28M -8.83M -7.98M -7.64M -13.96M -945M -94.02M -37.65M -453M -38.6M -37.78M -1.62B
Logo Racura Oncology Ltd
Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.
Employees
-
Date Price Change Volume
11/03/26 2.360 $ +1.72% 28,964
10/03/26 2.320 $ -0.85% 31,028
09/03/26 2.340 $ -4.88% 181,563
06/03/26 2.460 $ 0.00% 154,820
05/03/26 2.460 $ +7.89% 106,387

Annual profits - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW